Dear All, GVK BIO in collaboration with Quantitative Solutions (QS), have developed Schizophrenia Clinical Trial Outcome Database. The database captures summary level data for the clinical safety and efficacy outcomes from publicly available data sources (Journal publications, Clinical trial registries, Conference posters, Regulatory reviews, etc.).
The database includes clinical safety and efficacy information on both second-generation antipsychotics (SGAs) currently approved or in development for the first-line monotherapy treatment of schizophrenia and on anti-psychotics used for the second-line treatment (monotherapy or add-on) in treatment-resistant or refractory schizophrenia patients. Information on first-generation antipsychotics (FGAs) such as haloperidol are included if they were used as active controls. To give a brief summary of the content: Parameter Description Format Excel Indications Schizophrenia #Trials/References 114/128 # Patients 28,955 # Rows of Data 13,708 Last Updated Sept, 2010* Compounds risperidone, paliperidone, quetiapine, ziprasidone, asenapine, aripiprazole, olanzapine, chlorpromazine, haloperidol, sertindole, clozapine, iloperidone, remoxipride, zotepine, cariprazine, methotrimeprazine, zotepine, fluoxetine, sulpiride, estradiol, mirtazapine, fluvoxamine, fluphenazine,ginkgo biloba, dehydroepiandrosterone, celecoxib, perphenazine, lamotrigine, CX516, donepezil, LY2140023, selegiline, amisulpride, ritanserin, pregnenolone and lurasidone. Key efficacy end points PANSS, BPRS, BPRSd, CGI, GAF, SANS, NSA-16, Response, Relapse Key safety end points ESRS, SAS, AIMS, BARS, SWN, adverse event percentages, and treatment discontinuations/required medication *The first version 1.0 was released last September 2009, and the Database was updated in September 2010, version 2.0. Key Advantages: · Models derived from Database can be used to characterize the probability distribution of clinical efficacy and tolerability as a function of various treatment and patient factors. · The database can help companies conduct comparative efficacy and safety analysis, link/scale biomarkers to clinical outcomes, predict/improve trial outcome, and develop product differentiation strategies. · The database is supported by customization and M&S consulting services provided by GVK Bio and QS, respectively, to ensure maximum flexibility and benefits to our clients · Kindly revert back for any further details on the Database and its utility Kindly revert back for any further details on the Database and its utility Best regards, Satish Satish Patil Manager, Sales & Marketing GVK Biosciences Pvt. Ltd., S-1, Phase-1, Technocrats Industrial Estate, Balanagar, Hyderabad - 500 037 Ë+91-9177991172 | ': 040-40212953 | *: [email protected]<mailto:[email protected]> Notice: The information contained in this electronic mail message is intended only for the use of the designated recipient. This message is privileged and confidential. and the property of GVK BIO or its affiliates and subsidiaries. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this message in error and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone +91-40-66929999 and destroy any and all copies of this message in your possession (whether hard copies or electronically stored copies).
